SandboxAlonso

Sotalol
BETAPACE® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Clinical Studies
How Supplied/Storage and Handling
Labels and Packages
SOTALOL HYDROCHLORIDE® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Sotalol
ClinicalTrials.gov

SandboxAlonso

Clinical data
Pregnancy category	US: B (No risk in non-human studies)
Routes of administration	oral
ATC code	C07AA07 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	>95%
Metabolism	Not metabolised
Elimination half-life	12 hours
Excretion	Renal Lactic (In lactating females)
Identifiers
IUPAC name N-[4-(1-hydroxy-2-isopropylamino- ethyl)-phenyl]-methanesulfonamide
CAS Number	3930-20-9
PubChem CID	5253
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C12H20N2O3S
Molar mass	272.3624 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

For patient information about Sotalol, click here.

Synonyms / Brand Names: BETAPACE, SOTALOL HYDROCHLORIDE

Overview

Sotalol (trade names Betapace and Betapace AF, Berlex Laboratories) is a drug used in individuals with rhythm disturbances (cardiac arrhythmias) of the heart, and to treat hypertension in some individuals.

Category

Beta Blockers

FDA Package Insert

BETAPACE (sotalol hydrochloride) tablet

Indications and Usage | Dosage and Administration | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Clinical Studies | How Supplied/Storage and Handling | Labels and Packages

SOTALOL HYDROCHLORIDE injection

Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Pharmacology

It falls into the class III antiarrhythmic agents because it inhibits the inward potassium ion channels in the heart. It is also a beta blocker because of its primary action on the β-adrenergic receptors in the heart.

By blocking the potassium channels, sotalol prolongs repolarization, therefore lengthening the QT interval and decreasing automaticity.

It also slows atrioventricular (AV) nodal conduction (beta-blocking effect).

Sotalol is a racemic mix of D and L enantiomers. The L-isomer is a beta blocker.

Sotalol is not selected for its beta-blocking ability, but rather for its Class III (potassium blocking) properties.

Indications

Sotalol is used to treat ventricular tachycardias as well as atrial fibrillation. Betapace AF is specifically labeled for atrial fibrillation.

Some evidence suggests that sotalol should be avoided in the setting of decreased ejection fraction due to heart attack.

See Also

• Antiarrhythmic agents
• Beta blocker